Senti Biosciences secures $53m funding to advance therapeutic design platform
Senti Biosciences has completed a $53m round of funding to support the expansion of their therapeutic design platform.
Senti Biosciences has completed a $53m round of funding to support the expansion of their therapeutic design platform.
BenevolentAI has acquired an advanced drug discovery and development facility on the Babraham Research Campus in Cambridge, UK, for an undisclosed sum.
A new collaborative project has been launched to develop a Zika virus vaccine that is suitable for use in pregnancy.
Gilead Sciences’ subsidiary Kite has agreed to use Sangamo Therapeutics’ zinc finger nuclease (ZFN) technology platform to develop cancer treatments in a collaboration deal worth over $3bn.
Scientists from Emulate and Roche have partnered to use Organ-Chips for testing of efficacy and safety of new antibody therapeutics and combination therapies.
ATUM has signed a patent licensing agreement, which gives Just Biotherapeutics access to its Leap-In cell line development tools.
Merck has agreed to acquire Australian biotechnology firm Viralytics, which is focused on developing oncolytic immunotherapy treatments for cancers, for about A$502m ($394m).
Swiss drugmaker Roche has agreed to acquire Flatiron Health, a US-based healthcare technology and services company, for $1.9bn.
Astellas Pharma has acquired Universal Cells for $102.5m in a move to utilize the latter’s technology to produce pluripotent stem cells that have the potential to lower immunological rejection in various therapeutic areas.
CureVac, a biopharmaceutical company focused on developing mRNA-based drugs, has been awarded two new grants from the Bill & Melinda Gates Foundation.